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Background. Metabolic effects following combination antiretroviral therapy (cART) vary by regimen type.
Changes in metabolic effects were assessed following cART in the AIDS Clinical Trials Group (ACTG) A5257
study, and correlated with plasma ritonavir trough concentrations (C24).
Methods. Treatment-naive adult subjects were randomized to ritonavir-boosted atazanavir or darunavir, or
raltegravir-based cART. Changes in lipids and other metabolic outcomes over time were estimated. Differences be-
tween arms were estimated with 97.5% confidence intervals and compared using pairwise Student t tests. Associa-
tions between ritonavir C24 and lipid changes at week 48 were evaluated via linear regression.
Results. Analyses included 1797 subjects with baseline fasting data. Baseline lipid profiles and metabolic syndrome
rates (approximately 21%) were similar across arms. Comparable increases occurred in total cholesterol, triglycerides,
and low-density lipoprotein cholesterol with the boosted protease inhibitors (PIs); each PI had greater increases relative
to raltegravir (all P≤ .001 at week 96). Metabolic syndrome incident rates by week 96 (approximately 22%) were not
different across arms. Ritonavir C24 was not different by arm (P = .89) (median, 69 ng/mL and 74 ng/mL in the ata-
zanavir and darunavir arms, respectively) and were not associated with changes in lipid measures (all P > .1).
Conclusions. Raltegravir produced the most favorable lipid profile. Metabolic syndrome rates were high at baseline
and increased to the same degree in all arms. Ritonavir C24 was not different in the PI arms and had no relationship
with the modest but comparable increases in lipids observed with either atazanavir or darunavir. The long-term clinical
significance of the lipid changes noted with the PIs relative to raltegravir deserves further evaluation.
Clinical Trials Registration. NCT 00811954.
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Contemporary antiretroviral therapy (ART) regimens
have improved virologic efficacy compared with earlier
therapies. However, less is known about how these reg-
imens compare to each other with respect to metabolic
outcomes. Given the need for lifelong therapy, data on
metabolic outcomes from randomized clinical trials can
provide useful information to guide the selection of
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first-line therapy. Ritonavir-boosted protease inhibitor (PI)–
containing therapy has been associated with the development
of dyslipidemia and insulin resistance that may predispose to
cardiovascular and cerebrovascular injuries [1–3]. On the con-
trary, raltegravir, an integrase strand inhibitor, has been shown
to have milder lipid and metabolic effects relative to PI-based or
nonnucleoside reverse transcriptase inhibitor–based therapy,
producing minimal changes in plasma lipid levels, insulin resis-
tance, or alteration of body habitus [4–6].
Furthermore, the extent of lipid and other metabolic changes
in ritonavir-boosted PI regimens may vary by regimen type and
by systemic ritonavir exposure [7]. Ritonavir is both a substrate
and an inhibitor of the cytochrome P450 (CYP) 3A isoenzyme
and, to a lesser extent, CYP2D6 [8]. All PIs vary in their affinity
and impact on CYP3A4 isoenzyme [9]. As higher ritonavir ex-
posure has been correlated with greater elevation in plasma lip-
ids and the occurrence of other metabolic side effects [10, 11],
the differential effect of coadministered PI on ritonavir plasma
concentrations could impact the lipid profile of a given ritona-
vir-boosted PI regimen.
The AIDS Clinical Trials Group (ACTG) Study A5257 evalu-
ated the virologic efficacy and tolerability of tenofovir disoproxil
fumarate (TDF)/emtricitabine in combination with ritonavir-
boosted atazanavir, raltegravir, or ritonavir-boosted darunavir
in treatment-naive human immunodeficiency virus (HIV)–
infected adults in the United States and Puerto Rico [12]. In
the current report, we examined the lipid and other metabolic ef-
fects of these 3 antiretroviral regimens, with the aim of evaluating
differences between the 2 PI arms, and between each of the PI
arms and the raltegravir arm. Additionally, in the 2 PI arms of
the study, the effects of atazanavir and darunavir on plasma
trough ritonavir concentrations (C24) and the association
between plasma ritonavir C24 and fasting lipid measures were
evaluated.
METHODS
Study Population and Design
ACTG A5257 was a phase 3, randomized, open-label trial in
which participants were randomly assigned 1:1:1 to receive 1
of 3 regimens—(1) 300 mg of atazanavir (Reyataz, Bristol-
Myers Squibb) plus 100 mg of ritonavir (Norvir, Abbott Labo-
ratories) once daily (ritonavir-boosted atazanavir); (2) 400 mg
of raltegravir (Isentress, Merck Inc) twice daily; or (3) 800 mg
of darunavir (Prezista, Janssen Therapeutics) plus 100 mg of ri-
tonavir once daily (ritonavir-boosted darunavir)—each with the
fixed-dose combination of 300 mg of TDF plus 200 mg of em-
tricitabine (Truvada, Gilead Sciences). This study was approved
by the biomedical investigational research committee at each
site, and all participants gave written informed consent before
study enrollment (ClinicalTrials.gov identifier NCT00811954).
The study population included ART-naive, HIV-1–infected
adults with plasma HIV-1 RNA level >1000 copies/mL. Study
evaluations were completed before entry; at entry; at weeks 4,
8, 16, 24, and 32; and every 16 weeks thereafter. Participants
were followed, regardless of meeting an endpoint, for 96 weeks
after enrollment of the last participant. The primary objective
of ACTG A5257 was to determine regimen equivalence with re-
gard to virologic efficacy and tolerability over 96 weeks. Study
A5257 had two important metabolic objectives. The first was
to compare the impact of the study regimens on a variety of met-
abolic measures including fasting plasma lipid and glucose levels,
prevalence of metabolic syndrome, and anthropometric mea-
sures. The study also aimed to detect an association between plas-
ma ritonavir C24 at steady state and 48-week changes in fasting
plasma lipid levels in the two ritonavir-boosted PI arms.
Fasting plasma lipid measurements evaluated included total
cholesterol (TC), high-density lipoprotein cholesterol (HDL-C),
triglycerides (TG), calculated non–HDL-C (calculated as TC –
HDL-C), and calculated low-density lipoprotein cholesterol
(LDL-C) (calculated as TC – [HDL-C + (TG/5)], if TG ≤400
mg/dL). Per protocol, these parameters were assessed at weeks
0, 24, 48, 96, and 144. Fasting was defined as nothing to eat or
drink for at least 8 hours except for water or decaffeinated
black coffee, and required prescription medications. Fasting
lipid profile levels were performed at any Clinical Laboratory Im-
provement Amendments–compliant laboratory. Steady-state
plasma ritonavir concentrations were evaluated by ritonavir C24
assessed once at least two weeks after initiation of ritonavir-
boosted atazanavir or ritonavir-boosted darunavir and obtained
within 22–26 hours after the last self-reported dose of ritonavir.
Sampling for ritonavir C24 continued until a target sample size of
258 participants with evaluable steady-state ritonavir C24
measures was reached. Concentrations were measured by liquid
chromatography–tandem mass spectrometry (LC-MS/MS)
as previously described [13] at the University of California,
San Francisco, on batched plasma samples. Incident metabolic
syndrome was assessed based on the National Cholesterol Educa-
tion Program (NCEP) Adult Treatment Panel III criteria [14, 15].
Statistical Analysis
Unless otherwise specified, all analyses included all eligible par-
ticipants with fasting lipid measures available at study entry but
otherwise followed the intention-to-treat principle; as-treated
analysis including participants who completed the study on
randomized treatment and sensitivity analyses excluding par-
ticipants on lipid-lowering medications (primarily aimed at
reducing TC, TG, and LDL) and antihypertensive agents were
also performed. Missing data were considered missing com-
pletely at random. Mean changes in fasting plasma lipid mea-
sures over time were estimated with 95% confidence intervals
(CIs). Pairwise treatment differences at weeks 24, 48, 96, and
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144 were estimated with 97.5% CIs and compared between the
treatment arms using pairwise Student t tests. The cumulative
probability of developing metabolic syndrome over time was es-
timated by Kaplan–Meier method. Participants not meeting cri-
teria for metabolic syndrome prior to end of follow-up were
censored at the time of their last visit requiring metabolic eval-
uation; participants meeting criteria for metabolic syndrome at
study entry were excluded from this analysis. All treatment
group comparisons were assessed at a 2.5% level of statistical
significance to provide modest control of the type I error in
the setting of multiple comparisons.
Ritonavir C24 was analyzed on the natural logarithm scales
and compared by treatment arms using Wilcoxon rank-sum
tests. Associations between ritonavir C24 and change from base-
line in levels of fasting TG, non–HDL-C, and calculated LDL-C
at week 48 and week 96 were analyzed using linear regression;
treatment-dependent associations were evaluated via 2-degrees
of freedom tests for different intercept and slope. For analyses of
these pharmacokinetic objectives, lipid values obtained follow-
ing discontinuation of ritonavir-boosted PI or initiation of
lipid-lowering agents were excluded, with values imputed with
the last observations obtained prior to these events. The target
sample size of 258 participants randomized to each of the rito-
navir-boosted PI arms provided 90% power to detect an associ-
ation between ritonavir C24 and 48-week change in fasting TG,
equating to a 32 mg/dL lower change in fasting TG over 48
weeks per 12.6 ng/mL lower ritonavir C24, and allowed for a
20% loss due to missing data (providing effective sample size
of 103 participants per ritonavir-boosted PI arm).
RESULTS
A total of 1809 evaluable participants were enrolled from 57
sites into A5257 between 22 May 2009 and 9 June 2011. Of
these, 1797 with confirmed baseline fasting samples and clinical
measures were included in the current analyses. Baseline demo-
graphics, metabolic and lipid measures, and clinical character-
istics of the study population were well balanced between
treatment arms (Table 1). The study population comprised
24% of women, 34% of non-Hispanic white, 42% of non-
Hispanic black, and 21% of Hispanic. Full demographic details
have been previously presented [9].
Eighty-eight percent of participants had the NCEP target TC
<200 mg/dL, 75% had TG <150 mg/dL, 89% had non–HDL-C
<160 mg/dL, and 89% (of 1170 with TG ≤400 mg/dL) had cal-
culated LDL <130 mg/dL, whereas only 43% had HDL-C ≥40
mg/dL. Median (Q1, Q3) fasting blood glucose level was 84 (78,
92) mg/dL; 89% had fasting blood glucose levels <100 mg/dL.
Twenty-one percent of participants had evidence of metabolic
syndrome at study entry. Fifty-eight percent of participants re-
ported a history of smoking, 38% reported a smoking history
>10 years, and 39% were current smokers. At study entry, 106
(6%) were taking lipid-lowering agents, 273 (15%) were taking
antihypertensive agents, and 64 (4%) were on hypoglycemic
therapy at study entry (Table 1).
Changes from baseline and absolute values over time in lipid
measures and other metabolic outcomes following therapy are
summarized in Figure 1, Supplementary Figure 1, and Table 2,
respectively. In pairwise comparisons, there were no differences
in the mean change from baseline to all study weeks (24,
48, and 96) in any of the lipid measures between the ritonavir-
boosted atazanavir and the ritonavir-boosted darunavir arms (all
P > .05). However, each of the ritonavir-boosted PI arms had
greater increases relative to the raltegravir arm in TC, TG,
non–HDL-C, and LDL-C (all P≤ .001). HDL-C increased mod-
estly in all 3 arms (an average increase of 6 mg/dL over 96 weeks),
with no significant differences in mean change from baseline to
all study weeks evaluated between treatment arms (all P > .06)
(Figure 1A–C, Supplementary Figure 1A). From baseline to
week 96, the percentage of participants who had taken lipid-
lowering agents increased from 5% to 11% in the ritonavir-boosted
atazanavir arm, 6%–9% in the raltegravir arm, and 6%–14% in
the ritonavir-boosted darunavir arm. Sensitivity analyses of
changes in lipid measures over time by treatment arms that in-
cluded as-treated analyses with participants who completed the
study on their original randomized treatment, or limited to par-
ticipants not taking lipid-lowering agents, yielded findings that
were consistent with the intention-to-treat analyses.
Fasting plasma glucose, waist circumference, and waist-to-
height ratio increased following ART initiation in all 3 treatment
arms (Figure 1D and 1E; Supplementary Figure 1B). In pairwise
comparisons, larger increases in waist circumferencewere observed
with the raltegravir arm compared with the ritonavir-boosted dar-
unavir arm at weeks 48 and 96 (all P≤ .023) but not compared
with the ritonavir-boosted atazanavir arm (P≥ .07); no other treat-
ment group differences were apparent. The cumulative probability
of incident of metabolic syndrome by week 96 was 21% (95% CI,
18%–26%) for the ritonavir-boosted atazanavir arm, 22% (95% CI,
18%–26%) for the raltegravir arm, and 22% (95% CI, 19%–27%)
for the ritonavir-boosted darunavir arm, with no apparent differ-
ence between the treatment arms (all P≥ .7; Figure 2).
Of the 230 participants who had plasma obtained for evalu-
ation of drug concentrations, 109 in the ritonavir-boosted ata-
zanavir arm and 121 in the ritonavir-boosted darunavir arm
had evaluable steady-state ritonavir C24. Median (Q1, Q3) rito-
navir C24 was 69 (40–105) ng/mL in the ritonavir-boosted ata-
zanavir arm, and 74 (38–110) ng/mL in the ritonavir-boosted
darunavir arm, with no apparent difference between the arms
(P = .89). Associations between ritonavir C24 and changes in
fasting plasma lipid measures were not apparent (P≥ .4) at ei-
ther week 48 or week 96. While treatment group specific esti-
mates of associations between ritonavir C24 and lipid change
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were in opposite directions (negative in the atazanavir group,
positive in the darunavir group; Supplementary Figure 2), none
of these associations were statistically significant (P > .09), and
no evidence of PI-specific associations was apparent (P≥ .09)
(Table 3).
DISCUSSION
In this prospective, randomized, open-label study evaluating ral-
tegravir and the two ritonavir-boosted PI regimens as initial treat-
ment of HIV infection, we identified differences in lipid changes
Table 1. Baseline Characteristics and Metabolic Parameters Among Fasted Subjects
Characteristic Total (N = 1797)
Treatment
ATV/r (n = 602) RAL (n = 600) DRV/r (n = 595)
Female sex 432 (24) 143 (24) 146 (24) 143 (24)
Age, y, mean (SD) 37.37 (11.02) 37.60 (10.84) 37.00 (10.81) 37.52 (11.40)
Race/ethnicity
White non-Hispanic 612 (34) 212 (35) 212 (35) 188 (32)
Black non-Hispanic 753 (42) 250 (42) 253 (42) 250 (42)
Hispanic (regardless of race) 385 (21) 124 (21) 115 (19) 146 (25)
Other 43 (2) 15 (2) 18 (3) 10 (2)
Weight, kg, mean (SD) 78.64 (18.36) 78.97 (18.92) 78.84 (18.49) 78.11 (17.66)
BMI, kg/m2, mean (SD) 26.14 (5.93) 26.22 (6.10) 26.26 (5.85) 25.94 (5.82)
Baseline HIV-1 RNA, log10 copies/mL, mean (SD) 4.63 (0.72) 4.63 (0.73) 4.65 (0.71) 4.60 (0.71)
Baseline CD4+ count, cells/µL, mean (SD) 308.45 (192.27) 309.16 (188.96) 306.07 (198.59) 310.15 (189.38)
Fasting TC, mg/dL
Median (Q1, Q3) 154 (133, 178) 154 (134, 176) 155 (134, 181) 154 (133, 179)
<200 mg/dL 1,589 (88) 537 (89) 523 (87) 529 (89)
Fasting HDL-C, mg/dL
Median (Q1, Q3) 38 (31, 46) 37 (30, 45) 38 (31, 46) 38 (31, 47)
>40 mg/dL 780 (43) 249 (41) 272 (45) 259 (44)
Fasting TG, mg/dL
Median (Q1, Q3) 103 (73, 148) 105 (74, 150) 103 (73, 146) 99 (73, 148)
<150 mg/dL 1,352 (75) 449 (75) 456 (76) 447 (75)
Fasting non-HDL-C, mg/dL
Median (Q1, Q3) 114 (95, 138) 115 (96, 137) 115 (96, 140) 112 (93, 138)
<160 mg/dL 1,606 (89) 542 (90) 533 (89) 531 (89)
Fasting calculated LDL-C, mg/dLa
Median (Q1, Q3) 92 (74, 112) 93 (75, 111) 93 (74, 115) 89 (73, 111)
<130 mg/dL 1,606 (89) 542 (90) 528 (88) 536 (90)
Fasting glucose, mg/dL
Median (Q1, Q3) 84 (78, 92) 85 (79, 93) 85 (78, 92) 83 (77, 91)
<100 mg/dL 1602 (89) 529 (88) 539 (90) 534 (90)
Presence of metabolic syndrome 381 (21) 141 (23) 121 (20) 119 (20)
Smoking status
History of smoking 1,044 (58) 358 (59) 349 (58) 337 (57)
Smoking history >10 y 678 (38) 249 (41) 225 (38) 204 (34)
Current smoker 706 (39) 251 (42) 241 (40) 214 (36)
On lipid-lowering treatment 106 (6) 33 (5) 35 (6) 38 (6)
On antihypertensive agents 273 (15) 95 (16) 89 (15) 89 (15)
Hypoglycemic agents 64 (4) 24 (4) 21 (3) 19 (3)
Data are presented as No. (%) unless otherwise specified.
Abbreviations: ATV/r, ritonavir-boosted atazanavir; BMI, body mass index; DRV/r, ritonavir-boosted darunavir; HDL-C, high-density liproprotein cholesterol; HIV-1,
human immunodeficiency virus type 1; LDL, low-density liproprotein cholesterol; RAL, raltegravir; SD, standard deviation; TC, total cholesterol; TG, triglycerides.
a Calculated as [fasting calculated LDL-C (mg/dL) = fasting TC – fasting HDL-C – (fasting TG/5)], only for subjects with fasting TG ≤400 mg/dL; subjects with fasting
TG >400 mg/dL were excluded.
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Figure 1. Mean changes from baseline in metabolic outcomes and anthropometric measures, over time, with 95% confidence interval. Abbreviations:
ATV/RTV, ritonavir-boosted atazanavir; Diff, difference; DRV/RTV, ritonavir-boosted darunavir; LDL-C, low-density lipoprotein cholesterol; RAL, raltegravir.
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and anthropometric changes between treatment regimens. As ex-
pected based on prior small studies, we found increases in fasting
lipid measures including TC, TG, non–HDL-C, and LDL-C fol-
lowing therapy with the two ritonavir-boosted PI arms but not
with the raltegravir arm. These lipid changes were similar at
every study evaluation point between the two ritonavir-boosted
PI arms, confirming previously reported equivalence in the
lipid effects of these two widely used PI regimens in clinical prac-
tice [16].Of note, the mean HDL-C level was low in the majority
of participants at entry, as expected for ART-naive subjects [17].
However, small increases were observed for this lipid measure in
all 3 arms with no apparent differences between arms, also con-
sistent with prior data suggesting that initiation of ART modestly
improves HDL-C levels [17].
Metabolic syndrome is a term that describes a cluster of clin-
ical, anthropometric, and laboratory measures that confer height-
ened risk of cardiovascular disease and type 2 diabetes [18].There
is a relatively high prevalence of metabolic disorders among
HIV-infected individuals [19], which has been attributed to
lipid abnormalities, particularly high plasma TG and low
HDL-C commonly seen in untreated HIV disease [20],and to an-
tiretroviral-induced metabolic and body shape changes [21, 22].
At baseline, the fasting lipid profile was below NCEP lipid thresh-
olds for individuals with one or more cardiovascular risk factors
for a large proportion of participants, fasting blood glucose levels
were <100 mg/dL in 89%, and the use of hypoglycemic agents
was modest. The presence of pretherapy metabolic syndrome
was high (21%), and similar to that previously reported for
HIV-infected individuals [23, 24]. In contrast to the general pop-
ulation, among whommetabolic syndrome is primarily driven by
hypertension, hyperglycemia, and abdominal obesity [25], base-
line metabolic syndrome in this study was driven largely by a
combination of low plasma HDL-C levels and hypertriglyceride-
mia—two lipid parameters directly affected byHIV infection [17].
Table 2. Summary of the Absolute Levels: Treatment Group Comparison of Lipids Over Time
Metabolic Parameters Study Week
ATV/r RAL DRV/r
Mean (95% CI) Mean (95% CI) Mean (95% CI)
Fasting total cholesterol, mg/dL 0 156.7 (154.0–159.4) 158.3 (155.4–161.2) 157.0 (154.0–160.0)
24 166.3 (163.1–169.4) 157.9 (154.9–160.9) 169.2 (166.1–172.3)
48 169.8 (166.4–173.2) 159.5 (156.5–162.4) 172.3 (168.9–175.6)
96 172.3 (169.0–175.6) 163.4 (160.3–166.4) 172.4 (169.0–175.8)
Fasting HDL-C, mg/dL 0 38.8 (37.8–39.8) 39.5 (38.3–40.6) 40.4 (39.2–41.5)
24 43.4 (42.2–44.6) 43.9 (42.7–45.0) 44.4 (43.1–45.7)
48 45.1 (43.8–46.5) 44.5 (43.3–45.7) 45.9 (44.6–47.1)
96 45.2 (43.9–46.5) 45.4 (44.2–46.7) 45.6 (44.2–47.0)
Fasting triglycerides, mg/dL 0 123.8 (117.2–130.4) 123.4 (116.9–129.9) 124.3 (117.1–131.5)
24 140.3 (133.0–147.6) 109.3 (103.4–115.2) 137.3 (129.7–144.9)
48 139.7 (132.1–147.4) 115.3 (108.8–121.9) 139.5 (131.3–147.6)
96 140.9 (133.0–148.8) 116.3 (109.6–122.9) 141.1 (131.1–151.1)
Fasting non–HDL-C, mg/dL 0 117.9 (115.4–120.4) 118.8 (116.2–121.5) 116.6 (113.9–119.3)
24 122.9 (119.9–126.0) 114.0 (111.1–116.9) 124.8 (121.8–127.9)
48 124.6 (121.4–127.9) 115.0 (112.1–117.8) 126.5 (123.2–129.7)
96 127.1 (123.9–130.3) 118.0 (114.9–121.0) 126.9 (123.6–130.1)
Fasting calculated LDL, mg/dL 0 93.7 (91.4–96.0) 94.9 (92.4–97.5) 93.0 (90.5–95.4)
24 95.4 (92.8–98.1) 92.2 (89.7–94.7) 98.0 (95.3–100.6)
48 97.4 (94.5–100.2) 92.0 (89.6–94.3) 99.1 (96.3–101.9)
96 99.4 (96.5–102.3) 95.1 (92.5–97.7) 99.9 (97.1–102.7)
Fasting plasma glucose, mg/dL 0 88.0 (86.2–89.8) 87.4 (85.6–89.2) 85.6 (84.0–87.1)
24 90.3 (88.1–92.5) 89.2 (87.4–91.0) 88.9 (87.0–90.9)
48 89.5 (87.9–91.2) 89.0 (86.8–91.3) 87.0 (85.6–88.5)
96 90.2 (88.3–92.2) 88.6 (87.0–90.3) 88.9 (86.9–90.9)
Waist:height ratio, cm:cm 0 0.53 (.52–.53) 0.53 (.52–.53) 0.52 (.51–.53)
24 0.54 (.53–.54) 0.54 (.53–.54) 0.53 (.52–.53)
48 0.54 (.53–.55) 0.54 (.54–.55) 0.53 (.52–.54)
96 0.55 (.54–.55) 0.55 (.54–.56) 0.53 (.52–.54)
Abbreviations: ATV/r, ritonavir-boosted atazanavir; CI, confidence interval; DRV/r, ritonavir-boosted darunavir; HDL-C, high-density lipoprotein cholesterol; LDL, low-
density liproprotein cholesterol; RAL, raltegravir.
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During the study, the cumulative probability of developing
new metabolic syndrome was high (approximately 22% at 96
weeks). However, contrary to expectation due to the known
effects of ritonavir-boosted PI regimens on lipids, no differences
between the study arms were apparent. The greater increase in
waist circumference observed with the raltegravir-based therapy
counterbalanced the contribution of higher TG levels in the PI
arms, accounting for the comparable cumulative probability of
metabolic syndrome in all three treatment arms. This notwith-
standing, the high rate of metabolic syndrome at baseline and
following ART in this population should raise some concern,
as individuals with metabolic syndrome are susceptible to a
Figure 2. Cumulative probability of metabolic syndrome, by treatment group. A total of 1363 subjects were included in this analysis; 381 subjects who
had metabolic syndrome at baseline and 53 subjects who were censored at baseline were excluded. Abbreviations: ATV/RTV, ritonavir-boosted atazanavir;
DRV/RTV, ritonavir-boosted darunavir; RAL, raltegravir.
Table 3. Linear Regression Estimates Evaluating the Association Between Plasma Ritonavir Trough Concentrations and Changes in Lipid
Parameters Over 48 and 96 Weeks
Parameter
LDL TG Non-HDL
Estimate (95% CI) P Value Estimate (95% CI) P Value Estimate (95% CI) P Value
Associations with change to week 48, mg/dL
Intercept 3.78 (−0.02 to 7.57) . . . 15.85 (5.17–26.52) . . . 8.21 (4.10–12.31) . . .
RTV C24 (per 1 log [ng/mL])
a 0.51 (−1.58 to 2.61) .63 1.71 (−4.25 to 7.68) .57 0.99 (−1.30 to 3.28) .40
Test for PI-specific association (2 df) P= .09 P= .23 P= .10
Associations with change to week 96, mg/dL
Intercept 4.23 (0.30–8.16) . . . 17.45 (6.18–28.73) . . . 8.87 (4.54–13.20) . . .
RTV C24 (per 1 log [ng/mL])
a −0.15 (−2.28 to 1.99) .89 −0.14 (−6.36 to 6.08) .97 −0.25 (−2.63 to 2.14) .84
Test for PI-specific association (2 df) P= .53 P= .35 P= .22
Estimates (mg/dL) are from simple linear regression analysis of RTV C24 on change from baseline to the given week for each lipid parameter. RTV C24 values (on the
natural log scale) were centered on the group mean for modeling, so the intercept estimate represents the average lipid change from baseline for an average
(geometric mean) RTV C24 of approximately 55 ng/mL. The test for a PI-specific association is a 2-df F test for nonzero treatment group main (intercept) and
interaction (RTV C24 × treatment) coefficients.
Abbreviations: C24, plasma trough concentration; CI, confidence interval; df, degrees of freedom; HDL, high-density lipoprotein; LDL, low-density lipoprotein; PI,
protease inhibitor; RTV, ritonavir; TG, triglycerides.
a Estimate represents the estimated difference in the lipid change from baseline to given week for each 1-log (natural) difference in RTV C24; note that 1 log is
approximately the difference between the first and third quartiles of observed RTV C24 in the A5257 study.
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variety of conditions including cardiovascular diseases, type 2
diabetes, certain malignancies, polycystic ovarian syndrome,
and reactive airway disease [26–28].
The lipid changes experienced with ritonavir-boosted PI ther-
apy are speculated to be driven to a larger extent by the ritonavir
component of the regimens. In the TMC114-C159 trial [29], ri-
tonavir-boosted atazanavir increased the plasma exposure of rito-
navir, whereas ritonavir-boosted darunavir had an opposite
effect. That healthy volunteer study with only 28 days’ duration
could not evaluate the metabolic consequences of this differential
ritonavir systemic exposure. The present study provided an op-
portunity to rigorously evaluate this question. Steady-state rito-
navir trough concentrations in our study population were
comparable to previous reports for the tablet formulation [30],
and were not different between the ritonavir-boosted atazanavir
and darunavir regimens. Associations between ritonavir exposure
and lipid changes over 48 and 96 weeks were also not apparent
(both overall and within specific PI regimens). Several reasons
may account for the differences between our findings and the
TMC114-C159 trial, including the larger size of our study
population, which may have limited the confounding effect of
intrasubject variability in drug concentrations; the use of HIV-
infected rather than healthy volunteers; and the longer study
follow-up time points at which lipid sampling was performed
in the current study. It should also be noted that it is possible
that ritonavir exposure may affect other metabolic outcomes
other than plasma lipids, although the scant published literature
to date does not support an association between ritonavir con-
centration and changes in anthropometric measurements [31].
The diversity of the study population with relatively high pro-
portions of women and participants of ethnic minority back-
grounds, which closely mirrors the demography of the HIV/
AIDS epidemic in many parts of the United States, makes
these findings of the current analyses generalizable to clinical
practice. Furthermore, the pharmacokinetic/pharmacodynamic
analysis included a robust sample of >200 ritonavir C24 samples
collected within a specific time interval. This robust sample size
is large enough to militate against the confounding effect of in-
trasubject variability in plasma antiretroviral concentrations
that have limited the interpretation of previous smaller studies.
In addition, this study captured data from baseline to week 144,
allowing a longer assessment of changes in metabolic measures
relative to other studies. Self-reported adherence to ART and
nonobservance of ritonavir administration prior to pharmaco-
kinetic sampling limits nearly all studies of this type. Fasting
plasma lipid fractions were limited only to TC, TG, non–
HDL-C, LDL-C, and HDL-C. Typically, dual-energy X-ray ab-
sorptiometry (DEXA) data are used to assess changes in body
fat composition with therapy. However, DEXA scans were not
obtained in the general study participants, but were obtained on
a subset of participants and will be reported separately.
In this large, randomized prospective trial, raltegravir pro-
duced the most favorable lipid profile compared with 2 ritona-
vir-boosted PIs. Metabolic syndrome rates at baseline were high,
and the cumulative probability of developing new metabolic
syndrome post-ART was similar across all arms. Ritonavir C24
was not different between the 2 ritonavir-boosted PIs arms, and
had no relationship with the modest but similar increases in
plasma lipids observed with either the ritonavir-boosted ataza-
navir–based or ritonavir-boosted darunavir–based regimen.
The long-term clinical significance of the lipid changes noted
with the two ritonavir-boosted PI regimens relative to the ralte-
gravir-based regimen deserves further evaluation, particularly
when initiating ART in patients with high cardiovascular risk
profiles.
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